Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
In a study involving patients with Danon disease, AAV9.LAMP2B gene therapy appeared to be safe, increased cardiac LAMP2 expression, and was associated with clinical...
NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions....
Oral Infigratinib Therapy in Children with Achondroplasia
A phase 2 dose-finding study evaluated the safety and efficacy of infigratinib, an orally bioavailable FGFR1–3 selective tyrosine kinase inhibitor, in children with achondroplasia.
The...
NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Colchicine in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
